On December 10, Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven biotechnology company, hosted the fourth edition of its Pharma.AI Quarterly Launch webinar, titled “Epic Year-End Recap & Q4 Winter Updates”. The event drew more than 300 registrants from universities, healthcare institutions, global pharmaceutical companies, and innovative biotech firms worldwide.
Insilico's software team showcased the recap of Pharm.AI in 2025,and the latest capabilities through live demos and real‑world case studies.
Key highlights are summarized below:
Generative Biologics
What improved in 2025:
What's new in Q4:
Chemistry42/Nach01
What improved in 2025
PandaOmics
The single-cell dataset viewer and gene signature will come soon.
DORA:
Deep Research compresses the journey from idea to publication‑ready report. After you enter a topic and brief context in a chat interface, it builds a focused research plan and retrieves only high‑quality sources, scored by peer‑review status, author expertise, and relevance, each with a traceable link to the original.
It then applies advanced reasoning to synthesize cross‑domain knowledge, resolve contradictions, and surface hidden questions, exposing a transparent chain of thought behind every conclusion. It produces a concise, analyst‑level report with clearly structured key insights, supporting evidence, and actionable recommendations within minutes. The report opens in DORA, where you can refine, polish, and extend it with built‑in AI tools before using it for decisions or publication.
MMAI GYM for Science:
MMAI GYM is a place where you can send any AI model to train and become an expert in real-world drug development tasks with high-performance. It combines proprietary multi‑omics datasets, patents, papers, clinical readouts, and domain‑specific reinforcement learning to teach models how to work natively with biochemical formats, understand complex R&D tasks and operate constraints of biology, safety, efficacy, and synthesis. Dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10× performance gains on key drug discovery benchmarks.
In 2016, Insilico first described the concept of using generative AI for designing novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since then, Insilico has continued to integrate technical breakthroughs into the Pharma.AI platform, which is now a generative AI-powered solution encompassing biology, chemistry, medicine development, and scientific research. Powered by Pharma.AI, Insilico has nominated over 20 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of more than 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated a significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-edge automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across various industries, including advanced materials, agriculture, nutritional products, and veterinary medicine.
For more information, please visit www.insilico.com .